Documente Academic
Documente Profesional
Documente Cultură
Patrel Berceanu
Pe un perete de manastire, Mai caut lumina palmei calde a mamei... Mi-as lipi sufletul de zid s-o mai simt, salvatoare.... Pe o geana de lumina mai sper, Sa vina intaia zi a nelinistii Mai vreau chipul sa ti-l ador in taina Dar taina s-a mutat parasita-n alt cer
Nu ma mai pot intoarce, cum nu mai pot lua Nicio dimineata de la capat.... Mereu pierd geana lunii ce pleaca si pierd invazia soarelui de frica infernului zgomotos pe care lumea noua-l revarsa, peste toate inimile, peste toate soaptele, catre toate tainele.... Totul se grabeste spre uitare, Ceasuri trec, ceasuri vin, ceasuri tac:tic-tac....
Bolile alergice reprezinta a cincea cauza de boli cronice la toate varstele A 3-a cauza de boli cronice la copii sub 18 ani, afectand pana la 1 din 3 copii
Statisticile
indica faptul ca pana in 2015 jumatate din populatia europeana va suferi de o alergie .
EPIDEMIOLOGIE
Datele epidemiologice sunt controversate Global 1/3 din populaie are o problem de alergie alimentar, nord-americani 10% Diagnostic precizat in 1-2%. La copii variaz n limite mai largi - 0,3 - 7,5% - 0-3 luni - 8% (Franta) - 3 luni-1 an - 2% - 1-2 ani - 2,5% IPLV - prevalen stabil de 2,5% in ultimii 20 de ani si chiar la cei alaptati (2,5%).
STUDII AMERICANE SI EUROPENE PREVALENTA - ADULTI 1,3 - 2%; - COPII 0,3 - 7,5% PREVALENTA ALERGIEI ALIMENTARE LA COPIL - N PRIMELE 3 LUNI VIATA = 5-8% (FRANTA) - IPLV 2% (STUDIU SCANDINAV) - IPLV SUB VARSTA 2 ANI = 2,5% IN RELATIE CU ORGANUL TINTA - TRACTUL G-I 50-80% - CUTANAT 20-40% - APARAT RESPIRATOR 10-25% - SISTEMIC RAR DIMENSIUNEA PSIHOSOCIAL CONFERA IMPORTANTA
Dependenti de pattern-ul alimentar Lapte (sugari) 2,5% Arahide/nuci populatia generala 1,1%
REACTII LA ALIMENTE
ADEVARATE ALERGII ALIMENTARE
INTOLERANTE ALIMENTARE
TOXICITATE ALIMENTARA
Intoleranta alimentara
Alergie alimentara
Non-IgE mediata
REACII DE INTOLERAN
NEIMUNOLOGIC (CEL MAI FRECVENT) - DEFICIT ENZIMATIC (INTOLERANTA LACTOZ) - DIMINUARE SUPRAFA DE ABSORBIE
IMUNOLOGIC (GLUTEN)
REACII TOXICE
REACII NETOXICE
MEDIATE IgE
NON IgE
ENZIMATICE FARMACOLOGICE
NEDEFINITE
PSIHOLOGICE
NEUROVEGETATIVE
IMUNOLOGICE? FIZICO-CHIMICE
ou
Lapte arahide
Nuci
8 alergeni
= 90% alergii alimentare Grau Diverse crustacee
Peste
Soia
Alergia alimentara
Cei mai obisnuiti alergeni alimentari: Copii
Lapte de vaca, grau, soia, ou, alune Responsabile de peste 90% din reactiile alergice
Adulti
Fiziopatologie
Alergenii alimentari glicoproteine hidrosolubile rezistente la incalzire si proteoliza GM 10-70 kDa absorbtie facila prin mucoase Purificate
Alune: Ara h1, Ara h2, Ara h3 Albus ou: Gal d1, Gal d2, Gal d3 Soia: Gly m1 Peste: Gad c1; crab: Pen a1
FIZIOPATOLOGIE
N ALERGIA ALIMENTAR SE CONFRUNTA:
proteinele laptelui de vac - cazeina - proteine solubile: -lactoglobulina, -lactoglobulina, serum albumina bovin, imunoglobuline bovine proteine din ou - ovomucoid - ovalbumina - lizozim proteine din soia - fraciuni globulinice 2s, 7s, 11s - inhibitori ai tripsinei - lectina
proteine de pete i produi marini - Gad Ch (morun) Met e1, Pen ai Pan 5l (crevete) - Hom Al (langust); Cha/z1 (crab) - fructe de mare proteine din arahide/alune - Ara h1, Ara h2, Ara h3 altele: - vac, porc - fasole - nuci, semine, cacao, ciocolat - citrice, mr, cpuni - gru i alte cereale (atenie, fina de gru!) - condimente, drojdie
Lapte de vaca Galbenus de ou Alune Soia boabe Peste Mazare verde Orez Rosii
= = = = = = = =
-lactoglobulina,etc Lipoproteina Alune I + altele Glicinina + altele Alergenul M Albumina Gluteina / globuline Glicoproteine
Sindromul latex-fructe
30-50% din indivizii alergici la latex prezinta hipersensibilitate asociata la unele alimente, in special fructe: avocado, banane, arahide, kiwi, rosii, cartofi. Nu este clar care este alergia primara: la latex sau hipersensibilitatea la fructe???
Factori genetici
Factori de mediu
REACIE TIP I:
REAGINIC
ALERGIA ALIMENTAR CONSECINA: - REACII MEDIATE IgE - REACII NON IgE - MEDIATE CELULAR SENSIBILIZAREA ARE LOC LA PRIMA EXPUNERE LA ANTIGEN:
SENSIBILIZARE
DUP MIGRARE PRIN MUCOAS PROTEINELE STRINE CAPTATE DE CELULELE PREZENTATOARE DE ANTIGEN: - MACROFAGE - CELULE DENDRITICE
REEXPUNERE
O NOU EXPUNERE Ag ELIBERARE DE MEDIATORI LEGAI DE Ac IgE LA RECEPTORI (MASTOCITE, BAZOFILE, MACROFAGE)
PRECOCE
TARDIVA
Picasso, Guernica
HISTAMINA
REACIE IMEDIAT
REACIE TARDIV
ALERGIA ALIMENTAR INCLUDE NTOTDEAUNA REACIA MEDIAT IgE DE TIP I DAR NU ESTE LIMITAT NUMAI LA ACEST TIP DE HIPERSENSIBILITATE
patog
Efectele histaminei
Celula T IL-4
Chimiotaxie IL-5
Eozinofil
Cresterea activitatii fosfodiesterazei Scaderea nivelelor celulare de AMPc Cresterea eliberarii de mediatori si citokine Bazofil Celula B
Sinteza IgE
Eliberare de histamina
Monocit
Faza II: depunere CIC vase, leucocite, mediatori (amine vasoactive, leucotriene, PAF)
HIPERSENSIBILITATE TIP IV
MEDIAT DE LIMFOCITUL T ASPECTELE CLINICE INCLUD:
- DERMATITA DE CONTACT
- SIMPTOME PULMONARE CRONICE - SIMPTOME GASTROINTESTINALE
LEZIUNI EPITELIALE
MUCOASA
MEDIATORI CITOKINE
REACII IMUNE I. IgE: MASTOCITE II. IgG, CIC III. LT
GALT
CIRCULAIE SISTEMIC
FACTORI PREDISPOZANI
FACTORI CARE REGLEAZ HIPERSENSIBILITATEA ALIMENTAR LA COPIL I ADULT ALIMENTE SOLIDE
LAPTE
PREDISPOZIIE GENETIC
NOU NSCUT
ADULT
DE CE COPILUL?
IFN- IFN-
TH1
IL-2
B
IgA
Imunitate celular
Tr-1 / TH3
TH2
IL-10 TGF-
B
IgE
Toleran
Alergie
Dup Spiekermann et al., JPGN 2001; 32:237-55
Reactie imuna
Tip I Tip II
Raspuns imun
IgE IgG, IgM IgG si/sau complement Ly T (Th1) LyT (Th2)
Mecanism efector
Manifestari clinice
Degranulare Anafilaxie, urticarie, astm, mastocitara sdr. Lesoff Citotoxicitate Depuneri de complexe imune
Tip III
Monocite / macrofage
Eozinofile
Tip IVc
Tip IVd
LyT (CTL)
LyT
Exantem maculo-papular, Citotoxicitate bulos sau pustulos, eczema Neutrofile Exantem pustulos
Pilette Ch.Tests biologiques dans les maladies allergiques:interets et limites,Louvain Medical, 2005;124:5245-253 Buty JH. Lallergie allimentaire chez le nourisson et lenfant, Louvain Med, 122:S139-S151, 2003
87 10
8 3 5 2 1
Gastrita cu eozinofile
Esofagita cu eozinofile Hemosideroza pulmonara Sdr. Heiner Vasculita Henoch-Schnlein Crioglobulinemie Deficit imun complex absenta Rc IL-2
5-16 ani
5-16 ani 14-16 ani 3-10 ani 15-16 ani 6 ani
Studiu suedez 3104 copii evaluati prin chestionare la 2 luni, 1, 2, 4 si 8 ani Hipersensibilitate la alimente si alergie alimentara diagnosticata: 3.1% la 1 an si 7,6% la 8 ani Reactiile alergice la lapte, ou, peste si grau au scazut, in timp ce pentru alune si arahide au crescut Hipersensibilitatea alimentara la varsta mici a crescut riscul pentru astm bronsic, eczema si rinita alergica la varsta de 8 ani, chiar daca au fost luate masuri la acesti copii la varsta mica (<2 ani) Cresterea prevalentei hipersensibilitatii alimentare spre varsta de 8 ani probabil reflecta cresterea alergiei la polen de arbori si a reactiilor la alimente
Ostblom E, Lilja G, Pershagen G, Wickman M. Phenotypes of food hypersensitivity and development of allergic diseases during the first 8 years of life. Clin Exp Allergy. 2008 Aug;38(8):1325-32. Epub 2008 May 8.
Exist cel puin 2 fenotipuri diferite de IAPLV la copii: . De tip I indivizii sunt n cele din urm s poat rezilia rspuns Th2 i reactivitate clinice, rezultate n''''tranzitorii alergii alimentare . De tip II, persoanele fizice nu sunt n msur s downregulate rspuns Th2 i au alimente persistente alergie. Dac se confirm, aceasta ar trebui s ne schimbm abordarea la diagnosticul i managementul de alergie la lapte. Permiterea ingestie de produse lactate nclzite va mbunti dramatic calitatea de via pentru majoritatea subiecilor cu alergie la lapte de mult creterea varietate de produse alimentare pe care le pot consuma. Aceast schimbare dietetice ar facilita ndeplinirea cerinelor nutriionale, reduce anxietatea copilului, reduce disconfortul n situaii sociale, i ofer potenial o strategie eficient de a scurta timp pentru a atinge toleran naturale.
RELATIA CAUZALA
EVOLUTIE SI TERAPIE
TABLOU CLINIC
Diateza alergica
Dermatita atopica (Eczema)
Simptome gastrointestinale
Copii: falimentul cresterii
Alergie alimentara
Oboseala
MANIFESTRI CLINICE
SINDROAME
OC GASTROENTEROPATIA INDUS DE PROTEINE LA SUGAR I COPIL GASTROENTEROPATIE EOZINOFILIC ALERGIC ENTEROPATIA GLUTEN SENSIBIL
MANIFESTRI CLINICE
SINDROAME
MANIFESTRI CUTANATE - TUMEFIERI BUZE, ANGIOEDEM - PRURIT, RASH - URTICARIE, ECZEM - DERMATITA ATOPICA MANIFESTRI RESPIRATORII - STRNUT, RINOREE - WHEEZING, TUSE - BRONHOSPASM, - DISPNEE - LARINGITE
URTICARIE DERMATITA ATOPIC DERMATITA HERPETIFORM SINDROM DE ALERGIE ORALA SINDROM HEINER RINITE ALERGICE OTITE MEDII SEROASE(CONTROVERSE) CONJUNCTIVITE EDEM LARINGIAN BRONITE ASTM (RAR)
ALTE MANIFESTRI - TUMEFIERE ARTICULAR, MIGRENA, CEFALEE, APATIE, IRITABILITATE, HIPERKINEZIE, PROTEINURIE
Ig E
Mediate Ig E, debut acut
-Hipersensibilitate gastrointestinal imediat -Sindromul de alergie oral
Mixte
Non Ig E
II. Boli cu Ac IgE asociate cu reactii mediate celular, cu debut tardiv / cronic gastroenteropatia eozinofilica III. Boli mediate celular, cu debut intarziat / cronic
enterocolita la proteinele alimentare proctita la proteinele alimentare enteropatia la proteinele alimentare boala celiaca
HIPERSENSIBILITATE IMEDIAT GASTRO-INTESTINAL PATOGENIE: MEDIATA DE Ig E TRATAMENT: -ELIMINARE PROTEINE GENETICA: -FAMILIAL; -ADES ASOCIATA CU ALTE BOLI ATOPICE. ISTORIA NATURALA:
ANTICORPI Ig E
-80% VINDECARE
PRIN ELIMINARE DIN DIETA
-NECUNOSCUTA
Hematopoeza/supravietuire eozinofilica
GASTRITA CU EOZINOFILE
Leziune mucoasa
Varsaturi/diaree LE P Edeme periferice
Casexie
Perspective for Treatments of Food Allergy Early studies in humans demonstrated the potential risk of severe side-effects of conventional immunotherapy for food allergy.[16, 17]The recent development of animal models for food allergy has greatly enhanced the progress of research for potential treatments. Animal models have facilitated studies on several modalities in the treatment of food allergy (specific immunotherapy with modified antigens/epitopes; regulatory cytokines, e.g. IL-10 or IL-12; immunomodulatory microorganisms; immunomodulatory pharmaceutical agents; anti-IgE antibodies; DNA vaccination; Chinese herbal medicine). They have also been used to study the clinical outcome of specific treatments, and to research potential mechanisms involved in secondary tolerance acquisition. Chinese herbal medicine has provided interesting treatment options for several allergic conditions, including food allergy. The group by Liet al. [18] examined the protective effect of a food-allergy herbal formula called FAHF-1. They administered the formula to mice previously sensitized with peanut antigen in the presence of cholera toxin. Mice treated with FAHF-1 had no signs of anaphylaxis to antigen challenge, while sham treated mice experienced severe anaphylaxis. These results correlated with objective measurement of rectal temperature (which decreases during anaphylaxis). Measurement of biological parameters showed a decreased peanut-specific IgE antibody concentration in FAHF-1-treated mice compared to controls, as well as a decrease in IL-4, IL-5 and IL-13 production by splenocytes after antigen and mitogen activation. Interestingly, antigen-specific T-cell proliferation was maintained in the treated group. These promising results may need to be confirmed for other antigens, and further studies must be carried out to determine the active component(s) of FAHF-1, but, again, such studies show the interesting role of the T cell. As described above, a dysregulation or imbalance of Th1- and Th2-type responses might contribute to the pathogenesis of food allergy. Lee et al. [19] examined IL12 as a potential candidate in the treatment of peanut hypersensitivity. In a mouse model of food allergy, they orally administered liposome-encapsulated recombinant IL-12, either prior to, or following, sensitization of the mice with peanut antigen. They found that primary administration of IL-12 greatly diminished the production of peanut-specific serum IgE, while the same effect was seen to a lesser extent with secondary administration of IL-12. Primary administration of IL-12 also greatly reduced the clinical scores for anaphylaxis. These scores were also reduced to a lesser extent by secondary administration of IL-12. Regarding immunological parameters, peanut-specific IgG1 was greatly reduced in both treatments, while IgG2 levels were not significantly different. Splenocyte proliferation in response to the antigen was maintained in the IL-12-treated groups. However, significantly less peanut-specific fecal IgA was observed in both IL-12-treated groups. This work showed that, by administering a cytokine that shifts the immune response towards Th1, the investigators could either prevent or suppress the Th2-type response. Another potential approach for the treatment of food allergy might involve the immunomodulatory effects of microorganisms that may prevent allergy. Several clinical studies have shown the potential effect of lactobacilli strains in this regard. Shida et al. [20**] administered heat-killed Lactobacillus casei intraperitoneally to ovalbumin T-cell receptor-transgenic mice prior to antigen sensitization.[20**] They found an increased production of IL-12 in the group of mice given lactobacilli. The rise in IL-12 correlated with a decrease in IL-4 and IL-5 and an increase in IFN- production by splenocytes. Upon egg challenge, the clinical anaphylaxis score also decreased in the mice treated with IL-12. These results also correlate well with those of Lee et al. [19] showing a similar effect of orally administered IL-12. However, the administration of an IL-12-promoting bacterial strain might be a much easier approach in further therapeutic trials. The importance of T cells in food allergy is also demonstrated by the observation that infestation by helminths is protective against allergy. Bashir et al. [21**] examined the influence of administering Heligmosomoides polygyruson allergy by using a mouse model similar to the one described above. They found that the group of mice infected with H. polygyrus before sensitization had greatly diminished peanut-specific IgE levels and anaphylactic symptoms upon antigen challenge. Marked reduction of secretion of IL-13 by peanut specific T cells was also observed in the treated group. Furthermore, a role for IL-10 in clinical tolerance was observed. Taken together, these studies indicate a key role for modulation of T cell responses in the treatment of food allergy.
nelegerea noastr de implicare a limfocitelor B i T n alergiialimentare a progresat semnificativ n ultimii ani. Conceptul c unrspuns pur Th2 st la baza mecanismului de alergie alimentara a fost revizuit i nlocuit de teoria c dysregulation imunitar este lalocul de munc i ntr-un fel implic, de asemenea, Th1 i / saucelule TH0. n plus, un rol de citokine de reglementare, cum ar fiIL-10 este puternic sugerat, dar munca suplimentar va finecesare pentru a verifica variabile implicate n achiziionarea de toleran. recirculare a celulelor T este un proces dinamic, puternicinfluenat de prezena receptorii de suprafa, fie indic stareade activare a limfocitelor sau o preferin pentru homing de organe specifice, iar acest proces influeneaz n mod clarexpresia clinic de alergii alimentare. nelegerea noastr deepitop specifice Tcelul sau rspunsuri cu celule B a progresatfoarte mult n ultimii ani i pot contribui n viitorul apropiat lacrearea de teste de diagnostic i abordri mai bune de tratament.n cele din urm, modele de mouse-ul de alergii alimentare sunt un instrument nepreuit i s ofere noi perspective n mecanisme iterapii pentru alergii alimentare, la centrul de care, se pare, esterolul de rspunsuri T-celule.
December 14, 2009 (Buenos Aires, Argentina) Hypoallergenic formulas based on hydrolyzed cow's milk or combinations of amino acids have considerable variation in their biochemical and immunologic characteristics. The degree to which a given formulation is hypoallergenic can be identified and measured with sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), mass spectrometry, and the immunoglobulin (Ig)E reactivity of each formula. During their first year, 2% to 3% of infants develop hypersensitivity to cow's milk. This is frequently associated with early exposure to cow's milk. Formulas that lack allergenic activity and do not lead to harmful cytokine production are useful for preventing cow's milk sensitization and allergy in potentially sensitive children, according to Heidrun Hochwallner, a PhD candidate at the Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, in Austria, who presented her team's research here at the World Allergy Organization XXI World Allergy Congress. Scientists have investigated milk proteins for nearly 50 years, and note that sensitivity is more likely to occur in children with early exposure to cow's milk. Because more than half of allergic children have no family history of allergy, an effective way to prevent milk allergies might be to use hydrolyzed milk protein for all children who require breast milk supplements. The current study investigated 16 cow's milk formulas to determine their respective allergenic activity. The IgE reactivity of each formula was tested in sera from 22 patients with a cow's milk allergy; T-cell proliferation and cytokine secretion were examined in cultures of peripheral blood mononuclear cells from patients with cow's milk allergy and from people with IgG antibodies specific to cow's milk. Among the 16 formulas tested, "the amino acid formulations showed the lowest IgE-binding activity, low T-cell reactivity, and low allergenic activity," Ms. Hochwallner told Medscape Allergy and Immunology. In contrast, "the formulas with intact proteins, complete proteins, showed high levels of IgE-binding activity, Tcell reactivity, and allergenic activity," she said. "We could also see a difference in the induction of cytokine levels, so we could kind of identify formulas that induce lower levels than others of interferon-, interferon-, and [interleukin] IL-6. . . . And we could see formulas that induced lower levels of the Th2-driving cytokines IL-5 and IL-13," said Ms. Hochwallner. As summarized in the meeting abstract: "We could rank the various formulas regarding allergenic activity. Most interestingly, we could demonstrate that certain formulas did not stimulate a potential detrimental cytokine pattern, indicating that these formulas not only lack IgE-related inflammatory and sensitizing activity, but also do not induce harmful cytokine production." Is it odd that the standards for "hypoallergenic cow's milk formulas" are so varied? It is "somewhat surprising, but not really, because the manufacturing process varies from one manufacturer to another," session comoderator Sami Bahna, MD, DrPH, professor of pediatrics and medicine, chief of allergy and immunology, and director of the Allergy and Immunology Training Program, Louisiana State University Health Sciences Center, in Shreveport, toldMedscape Allergy and Immunology. "The molecules or the peptides that are remaining can vary widely for example, the extensively hydrolyzed whey. You may find casein in it, because the whey came from the whole milk," said Dr. Bahna. "Casein-derived formulas can have whey in them, but generally, they are hypoallergenic. Only about 3% to 5% of children who are allergic to cow's milk are allergic to the extensively hydrolyzed formula." "On the other hand, partially hydrolyzed formulas have larger peptides and can cause allergy. So although they are useful as . . . prophylaxis, they are not indicated. In fact, they are contraindicated for children who are already allergic," Dr. Bahna said. A person who is truly allergic to cow's milk or milk formula has to go to extensively hydrolyzed formula, and probably more than 95% of the formula on the market would be tolerated well. "If it's not tolerated, then they go to amino acid formulas," added Dr. Bahna. "Also, it depends on the availability, the society, the community, and the prices," explained Dr. Bahna. "The majority of cow's-milk-allergic children would tolerate soy formula, which is similar in price, and it's easily available and the taste is reasonable also. We have to individualize," Dr. Bahna said. "If a person is highly allergic, we may have to go to the very expensive or the amino acid formulas . . . so the individualization will be good for the family." In closing, the presenters noted that some formulas lack IgE-related inflammatory and sensitizing activity and do not induce production of harmful cytokines. The authors suggest that other types of inflammatory disease inflammatory bowel disease, for example might benefit from these noninflammatory milk formulations. Ms. Hochwallner and Dr. Bahna have disclosed no relevant financial relationships. World Allergy Organization XXI World Allergy Congress (WAC): Abstract 471. Presented December 7, 2009.
Astm bronsic 6%
Anafilaxia
Mecanisme:
Eliberarea IgE mediata a produsilor mastocitari Hymenoptera, alimente, penicilina, latex
Alergia alimentara
Aliment declansator, anafilaxie indusa de efort Rara Apare la 2-4 ore dupa ingestia anumitor alimente Apare la adolescenti decada 4 de viata M:F = 1:2 Alimente incriminate: grau, telina, crustacee, peste, fructe, lapte
Anafilaxie
PROBA NCRCARE: LIBER DUBLU ORB-PLACEBO-CONTROL REACIE IMUN RECDERE ACELEASI SIMPTOME
Definitie Ingestia in cantitati crescande a alimentului incriminat, la intervale fixe, sub observatie stricta
Skin-prick test (SPT) Cel mai rapid si cel mai ieftin Prag de sensibilitate mai mic decat CAP CAP IgE specifice mai mici de 0,1 sunt sugestive pentru test de incarcare negativ la majoritatea pacientilor 4 alimente: ou, lapte, alune, grau Simplu orb placebo controlat
Pre-teste
DIAGNOSTIC DE LABORATOR
TESTE
1)
ELIMINARE I NCRCARE
STANDARD DE AUR
Testul de incarcare orala Testul de incarcare dublu orb, placebo controlat gold standard pentru diagnosticul alergiei alimentare
1 ml pe brat, apoi pe coapsa ingestie 5 ml ingestie 10 ml ingestie 50 ml ingestie 100 ml etc. pana la doza zilnica necesara pentru varsta
A 6-a zi
A 7-a zi
Daca se produc reactii adverse, copilul este internat imediat si investigat; testul de incarcare este oprit.
dupa Erika ISOLAURI
A 11-a zi
A 12-a zi A 13-a zi A 14-a zi
LA DOMICILIU, INCEPEREA PROBEI DE INCARCARE CU AL DOILEA PREPARAT (PT/PP) DUPA MODELUL ANTERIOR
TESTE IMUNOLOGICE
2) A) IN VIVO TESTE CUTANATE ALERGOLOGICE
TESTE CUTANATE ALERGOLOGICE TESTE PRIN INTEPATURA -SKIN PRICK TEST (SPT) CU ANTIGEN DEFINIT TESTE PRIN ZGARIETURA SCRATCH TEST
REZULTATUL SE CITESTE LA 15-20 MIN REZULTAT POZITIV PAPULA DE CEL PUTIN 3 mm LA SUGAR 8 mm DATORITA PARTICULARITATII MASTOCITELOR CUTANATE NR REDUS, NIVELE IgE LIPSA EXTRACTELOR ANTIGENICE IMAGINAREA UNEI VARIANTE A TESTULUI PRICK PRICK TEST
VP NEG 95% - REZULTATELE NEGATIVE INFIRMA AA VP - POZITIVA 50% - REZULTATE POZITIVE POSIBIL SENSIBILIZARE
IN VITRO
ANTICORPI SPECIFICI IgE - RAST - CAP-RAST - ELISA - RIA ANTICORPI SPECIFICI IgG (IgA, IgM) - SPECIFIC ALIMENTARI - SE IGNOR
CIC, C1Q TESTUL TROFOTOP HISTAMINA PLASMATIC, TEST ELIBERARE A HISTAMINEI BAZOFILE (DETECIE INDIRECT A HISTAMINEI LEGATE DE BAZOFILE) - NU ESTE DE RUTIN, DOZAREA PROTEINELOR EOZINOFILE
The levels of IL-4 and IL-13, characteristic Th2-type cytokines, have been reported to show a tendency to be higher in the milk of allergic mothers than in that of nonallergic mothers [15], in contrast to the earlier finding by Rudloff et al. [133]. The reports on the levels of IL-8 [131] and IL-10 [133] showed similar results. Most recently, two papers have reported an association between low levels of TGF-b in mother's milk and development of IgE-mediated CMA or atopic eczema in breast-fed infants [134,135]. The levels of TGF-b were shown to correlate positively with the total number of IgA-producing cells in the peripheral blood of the infants [134] and with specific IgA antibodies to BLG and specific IgG antibodies to a-casein and whole formula, but negatively with the diameter of a SPT response to cow's milk and with lymphocyte indices to a-casein and BLG [135]. Based on their findings
RAST
Considerat mai putin sensibil decat testarea cutanata Recomandat: Pharmacia CAP-RAST Utilizat cand testele cutanate sunt contraindicate
BIOPSIA GASTRIC
BIOPSIA INTESTINAL
RECTOSIGMOIDOSCOPIE-BIOPSIE STUDIUL ABSORBIEI ZAHARURI - D-XILOZ ANALIZ SCAUN : - 1 ANTITRIPSIN - SNGE - GRSIMI CAROTEN SERIC
PRECIZARI PRACTICE
Testele cutanate nu detecteaza reactiile imunologice tardive, ci doar pe cele de tip IgE. Testele cutanate pozitive nu certifica o reactivitate simptomatica. Prick testul este edificator dupa prima luna de viata, dar depinde de puritatea alergenelor utilizate (trusa utilizata) Patch testul deceleaza reactiile tardive (dermatita atopica) Utilizarea combinata prick test si patch test creste semnificatia diagnostica in alergii Nici un test nu este perfect fiabil in APLV si criteriile clinice sunt infailibile
Valoare diagnostica in protocoale standardizate au testele de provocare la laptele de vaca dublu orb controlat placebo
Testele de provocare se efectueaza copiilor fara antecedente de anafilaxie Alergia alimentara impune supravegherea de catre pediatri experimentati, dieteticieni, iar introducerea unui nou aliment trebuie facuta cu prudenta, de obicei in spital.
Profesorul Tony Ferrante, imunolog la Children's Research Centre la University of Adelaide: test sanguin simplu care prezice daca nounascutii au risc crescut de dezvoltare a alergiilor pe masura ce
cresc
Alte domenii de interes: daca suplimentarea cu ulei de peste la gravide si imediat dupa nastere scade riscul alergiei ulterioare la copil
DIAGNOSTIC DIFERENIAL
COPII
ULCER PEPTIC COLECISTITA, COLELITIAZA DEFECTE ENZIMATICE (LACTAZA) FIBROZA CHISTIC, SDR. MALABSORBIE INFECII CRONICE: BACTERII, FUNGI, ALGETOXINETLBURRI GASTROINTESTINALE SEVERE; SIMPTOME NEUROLOGICE: - CL. BOTULINIC, STAFILOCOC AURIU, SALMONELLA, SHIGELLA, E. COLI, CAMPYLOBACTER
COPII
GIARDIAZA, TRICHINELOZA
REACII LA AGENI FARMACOLOGICI DIN ALIMENTE: - COFEIN; TEOBROMIN; HISTAMIN; TIRAMIN; SEROTONIN; FENILETILAMIN; ALCOOL ALIMENTE CONTAMINATE, ADITIVI ALIMENTARI: - TARTRAZINE; METABISULFIT DE Na - NITRII, NITRAI; BENZOAI - HIDROXITOLUEN BUTILAT - CONSERVANTE-SULFII - GLUTAMAT MONOSODIC ("CHINESE RESTAURANT SYNDROME)
DIAGNOSTIC DIFERENIAL
DERMATITA ATOPIC; TULBURRI CUTANATE
DERMATITA SEBOREIC ENTEROPATIA GLUTEN SENSIBIL ALTE CAUZE DE ECZEM: - SDR. WISKOTT-ALDRICH - AGAMAGLOBULINEMIA BRUTON - BOALA LEINER - HISTIOCITOZA X - ACRODERMATITA ENTEROPATICA - BOLI METABOLICE
MANIFESTRI ALERGICE SINO-PULMONARE
PROFILAXIE
PREVENTIA
IDENTIFICAREA SUGARILOR CU RISC ISTORIC FAMILIAL DE ATOPIE IgE CRESCUT N SNGELE CORDONULUI OMBILICAL
UN SINGUR PRINTE ATOPIC - RISC 25-35% AMBII PRINI ATOPICI - RISC 40-60% AMBII PRINI ATOPICI CU ACELEAI MANIFESTRI - RISC 50-80%
Picasso Alaptare
Bunic
Bunica
Bunic
Bunica
Tata
Mama
Copil
Copil
Copil
Copil
Beta-lactoglobulina
I. HIDROLIZATE PARIALE
- sunt denumite lapte hipoalergenic (HA) - conin lactoz i sunt potenial contaminate de proteinele laptelui - la rndul lor sunt de trei tipuri: Hidrolizate pariale ale proteinelor lactoserului (PLS): - Bleidilait HA - Gallia HA - Guigoz HA - Milumec HA - Modilac HA - Novalac HA 1 i 2 - Nidal HA 1 i 2 - Humana HA 1 i 2 Hidrolizate pariale mixte de PLS i cazein - Enfamil HA Hidrolizate pariale de PLS care nu poart meniunea HA: - Omneo 1 i 2 - Conformil 1 i 2 - Hidrolizat de soia i colagen de porc, dar care conine lactoz - Lactopregomin
+ + SANGERARE
NEEVALUARE VIITOARE
NEEVALUARE
CORTICOIZI
ANTIHISTAMINICE PERSPECTIVE ATC. ANTI IgE
Tratament
Eliminarea completa a agentului incriminat Plan de urgenta
Adrenalina
Doza
Adulti 0,3 0,5 ml IM 1:1000 repetata in 520 min daca e necesar Copii 0,01 mg/kg IM
Epinephrine (Adrenaline, EpiPen, TwinJect) DOC for treating anaphylaxis. Helps decrease symptoms of anaphylaxis by increasing systemic vascular resistance, elevating diastolic pressure, producing bronchodilation, and increasing inotropic and chronotropic cardiac activity. In addition, helps reduce urticaria, angioedema, laryngeal edema, and other systemic manifestations of anaphylaxis. Dosing Interactions Contraindications Precautions Adult 0.3 mL IM (also traditionally given SC) of 1:1000 aqueous injected (usual range is 0.2-0.5 mL) q10-15min, not to exceed 3 doses; may need to decrease dose to 0.2 mL in elderly persons or those with known cardiac conditions 0.3 mL IM of 1:1000 dilution q10-15min; IV route (1:10,000) seldom used; not to exceed 0.25 mg; given very slowly and with extreme caution 0.3-mg self-injectable devices (EpiPen, Twinject 0.3 mg)
Pediatric IM dosing in children based on weight or 0.01 mL/kg IM of 1:1000 dilution; not to exceed 0.3 mL IM 1:2000 dilution q1015min 0.15-mg self-injectable devices (EpiPen Jr, Twinject 0.15 mg)
Anafilaxie
Tratament agenti de linia a doua Antihistaminice
Blocante H1 Blocante H2
Anafilaxie
Daca este pe beta blocant, glucagon (1 mg bolus cu infuzie continua 1-5 mg/ora)
TRATAMENT - PRECIZARI
Mediata Ig E 86 % tolereaza formule pe baza de soia; Non mediata Ig E rata tolerantei este doar 50 %.
DURATA TRATAMENTULUI
Forme digestive:
Tratament scurt 15 zile; Tolereaza formula cu lactoza 29 %.
Anafilaxie 1 an.
H I P O A
Diversificare corecta!
Va evita:
Carne,nuci Faina de grau Ou si peste Arahide
COPIL ALERGIC
SOLUTII
PEDIATRU IMUNOLOG
ALERGENI
CAUZE
ALIMENTATIA NATURALA
PROBIOTICE
PROBIOTICE
FAO/OMS: MICROORGANISME VII EFECTE BENEFICE (FULLER, 1989) ELIE METCHNIKOFF = PREMIUL NOBEL PENTRU CONTRACARAREA FLOREI PATOGENE EFECTE DEMONSTRATE:
AMELIORAREA SEMNELOR DE ECZEMA ATOPICA LA COPIL MODULAREA ECHILIBRULUI MICROFLOREI INTESTINALE PRIN PROBIOTICE (COX2, PGE2, ACTIVITATE PROTEOLITICA)
STRATEGIE ACTUALA DE PREVENTIE A ALERGIEI ALIMENTARE INDUCEREA SI MENTINEREA TOLERANTEI ORALE LA BETALACTOGLOBULINA LACTOBACILLOS PARACASEI NCC 2461, BIFIDOBACTERIUM LACTIS NCC 362, LACTOBACILLUS JOHNSONII CONCEPT ACTUAL : PREBIOTICE PROBIOTICE - SINBIOTICE
PREBIOTICE
OLIGOZAHARIDE CARE CONTRIBUIE LA STIMULAREA NATURALA A CRESTERII BIFIDOBACTERIILOR SI BACILILOR LACTICI DIN INTESTIN CONTRIBUIE LA INTARIREA CAPACITATII DE APARARE SPECIFICA A ORGANISMULUI PRODUC ACIZI GRASI CU AJUTORUL BIFIDOBACTERIILOR
SI LACTOBACILILOR
Anticorpi monoclonali umanizati anti-IgE Imunoterapie cu alergeni proteici mutanti (inginerie genetica) Imunoterapie modulata de secventa antigen-imunostimulatorie (CpG) Imunoterapie peptidica Imunoterapie ADN-plasmidica Imunoterapie citokin-modulata Inducerea tolerantei sau imunoterapiei orale (lapte, ou, alune)
TERAPII DE VIITOR
Vaccinarea anti IgE
Tinte terapeutice: molecula IgE citokineTh2: IL-4, -5, -13, -33, -18 si limfopoietina stromala timica
Therapeutic vaccines against IgE-mediated allergies Lars Hellman Expert Review of Vaccines, March 2008, Vol. 7, No. 2, Pages 193-208
PROGNOSTIC
ACHIZIIA TOLERANEI CU VARSTA
PROGNOSTIC
TESTELE DE NCRCARE PENTRU ALERGIA ALIMENTAR SE VOR FACE: - DUP 12-18 LUNI PENTRU LAPTE VAC, OU, GRU - DUP 2-3 ANI PENTRU NUCI - DUP 3 ANI PENTRU ALUNE, PETE DUP 3 ANI 80% DIN SIMPTOMELE DE ALERGIE ALIMENTAR DISPAR ALERGIA LA LAPTE DISPARE DUP VRSTA DE 3 ANI LA 87% COPII ALERGIA LA ANUMITE ALERGENE POATE PERSISTA TOAT VIAA (NUCI, ALUNE, PETE)
CONCLUZII
ALERGIA ALIMENTARA ARE INCIDENTA IN CRESTERE, DEVINE O PREOCUPANTA PROBLEMA DE SANATATE PUBLICA
ALERGIA ALIMENTARA NECESITA CUNOASTERE, ABORDARE IN ECHIPA, TRATAMENT IN URGENTA (SOCUL ANAFILACTIC)
ASISTENTA COPILULUI SI A FAMILIEI ESTE ESENTIALA PENTRU SUCCESUL TERAPIEI
here are no surveys of population and geographical trends in food allergy in adults or children (though the situation is different in pediatric asthma and rhinitis) and this unmet need is particularly felt for CMA. The perception of milk allergy is far more frequent than confirmed CMA. Patient reports of CMA range between 1 and 17.5%, 1 and 13.5%, and 1 to 4% in preschoolers, at children 5 to 16 years of age and adults respectively. Cow's milkspecific IgE sensitization point prevalence progressively decreased from about 4% at 2 years to less than 1% at 10 years of age in the German Multi-Centre Allergy Study. The most reliable data in epidemiology are those from birth cohorts that are free from selection bias. There are 5 such challenge-confirmed studies. The CMA prevalence during infancy ranged from 1.9% in a Finnish study, 2.16% in the Isle of Wight, 2.22% in a study from Denmark, 2.24% in the Netherlands, and up to 4.9% in Norway. Patients with CMA develop gastrointestinal symptoms in 32 to 60% of cases, skin symptoms in 5 to 90%, and anaphylaxis in 0.8 to 9% of cases. This frequency of anaphylaxis is the main concern pointed out in many CMA studies. In a review, nearly one third of children with atopic dermatitis (AD) received a diagnosis of CMA after an elimination diet and an oral food challenge, and about 40 to 50% of children less than a year of age with CMA also had AD. Finally, with actual population and geographical trends remaining unknown, allergists are primarily in need of more detailed epidemiological surveys on a global scale. One large such epidemiological study supported by the European Commission is ongoing and aims to furnish the first prevalence data regarding the suspicion of CMA, sensitization to cow's milk, and oral food challenge-confirmed diagnosis in 10 European birth cohorts. Back to Top | Article Outline
n general, food allergy is more frequent in the pediatric, rather than the adult, population. According to a recent Japanese multicenter trial, the prevalence of CMA is 0.21% in newborns and 0.35% amid extremely premature babies (<1000 g).14 Food allergies are a cause of particular concern for children. Incidence is estimated to be greater in toddlers (58%) than it is in adults (12%).1517 Earlier prospective challenge-based studies have shown that in a population of 480 newborns followed up in the setting of a U.S. general pediatric practice through their third birthday, a parental report of 28% food allergy translates into a challenge-confirmed CMA rate of 8%,18,19 with 2.27 to 2.5% occurring in the first 2 years of life.
The number of studies on CM sensitization in unselected populations is limited. The meta-analysis carried out by Rona and colleagues23 identified 7 studies reporting a sensitization rate of 0.5 to 2% of preschoolers, of 0.5% at 5 to 16 years of age, and in less than 0.5% of adults.23,2533 In a later cohort of 543 children from the Isle of Wight followed-up from birth and tested at 1, 2, and 3 years of age, a positive milk sensitization test was found in 2 infants at 12 months (0.37%), in 5 at 2 years (0.92%), and in 3 at 3 years (0.55%).49 In the German Multicenter Allergy Study, 1314 children initially recruited were followed from birth for 13 years. The longitudinal data were analyzed for 273 children testing positive for serum cow's milk specific IgE antibody and were obtained at age 2, 5, 7, and 10. The point prevalence of sensitization to cow's milk progressively decreased from about 4% at 2 years to less than 1% at 10 years.50
http://www.slideshare.net/conp3
P@ul@-conp3